价格

TGF-b

未知生产厂商

生成 AI 研报

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

GENETICALLY ENGINEERED T CELLS WITH REGNASE-1 AND/OR TGFBRII DISRUPTION HAVE IMPROVED FUNCTIONALITY AND PERSISTENCE
EP 4397321 A3申请人: CRISPR THERAPEUTICS AG优先权: 2020
CN
EP
US
WO
14 件公开
METHODS OF MAMMALIAN RETINAL STEM CELL PRODUCTION AND APPLICATIONS
EP 3047017 B1申请人: UNIV CALIFORNIA优先权: 2013
CN
EP
US
WO
6 件公开
METHOD FOR ASSESSING VALIDITY OF CELL THERAPY PRODUCT
EP 3647782 B1申请人: KOLON LIFE SCIENCE INC优先权: 2017
CN
EP
US
WO
6 件公开
Antagonists of ligands and uses thereof
EP 2578684 B1申请人: NAT RES COUNCIL CANADA优先权: 2007
EP
US
WO
6 件公开
Cripto antagonism of activin and TGF-b signaling
US 7820620 B2申请人: RES DEV FOUNDATION优先权: 2004
US
6 件公开
Method for obtaining a TGF-beta enriched protein fraction in activated form, protein fraction and therapeutic applications
US 7141262 B2申请人: PIERRE JOUAN BIOTECHNOLOGIES SA优先权: 2001
US
5 件公开
SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT
EP 3840748 B1申请人: CLAVIUS PHARMACEUTICALS LLC优先权: 2018
EP
US
WO
4 件公开
CELL THERAPY COMPOSITIONS AND METHODS FOR MODULATING TGF-B SIGNALING
- EP 4291227 A2
  申请人: TAKEDA PHARMACEUTICALS CO优先权: 2021
  EP
  US
  WO
  4 件公开
- CN 117120077 A
  申请人: TAKEDA PHARMACEUTICALS CO优先权: 2022
  CN
Compositions and methods for modulating c-kit and PDGFR receptors
US 7678792 B2申请人: IRM LLC优先权: 2006
CN
US
4 件公开
Compositions and methods for inhibiting TGF-beta
US 7189733 B2申请人: MILLENNIUM PHARM INC优先权: 2004
US
4 件公开

药物

TGF-b

专利

CELL THERAPY COMPOSITIONS AND METHODS FOR MODULATING TGF-B SIGNALING